Veru to host investor call on january 4th, 2024 to discuss recent financing and strategy to prioritize the development of enobosarm as a combination treatment to prevent muscle loss and augment fat loss associated with weight loss glp-1 drugs

Miami, fl, dec. 19, 2023 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced it will host an investor conference call and audio webcast on thursday, january 4, 2024, at 8:00 a.m. et to discuss the recent financing and the company's strategy to prioritize the development of enobosarm for weight loss as well as provide an update on the company's drug pipeline.
VERU Ratings Summary
VERU Quant Ranking